The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer

Emily E. Bosco, Ying Wang, Huan Xu, Jack T. Zilfou, Karen E. Knudsen, Bruce J. Aronow, Scott W. Lowe, Erik S. Knudsen

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of human cancers and is aberrant in one-third of all breast cancers. RB regulates G1/S-phase cell-cycle progression and is a critical mediator of antiproliferative signaling. Here the specific impact of RB deficiency on E2F-regulated gene expression, tumorigenic proliferation, and the response to 2 distinct lines of therapy was investigated in breast cancer cells. RB knockdown resulted in RB/E2F target gene deregulation and accelerated tumorigenic proliferation, thereby demonstrating that even in the context of a complex tumor cell genome, RB status exerts significant control over proliferation. Furthermore, the RB deficiency compromised the short-term cell-cycle inhibition following cisplatin, ionizing radiation, and antiestrogen therapy. In the context of DNA-damaging agents, this bypass resulted in increased sensitivity to these agents in cell culture and xenograft models. In contrast, the bypass of antiestrogen signaling resulted in continued proliferation and xenograft tumor growth in the presence of tamoxifen. These effects of aberrations in RB function were recapitulated by ectopic E2F expression, indicating that control of downstream target genes was an important determinant of the observed responses. Specific analyses of an RB gene expression signature in 60 human patients indicated that deregulation of this pathway was associated with early recurrence following tamoxifen monotherapy. Thus, because the RB pathway is a critical determinant of tumorigenic proliferation and differential therapeutic response, it may represent a critical basis for directing therapy in the treatment of breast cancer.

Original languageEnglish (US)
Pages (from-to)218-228
Number of pages11
JournalJournal of Clinical Investigation
Volume117
Issue number1
DOIs
StatePublished - Jan 4 2007

Fingerprint

Retinoblastoma
Breast Neoplasms
Estrogen Receptor Modulators
Tamoxifen
Heterografts
Neoplasms
Cell Cycle
Tumor Suppressor Proteins
Retinoblastoma Protein
G1 Phase
Therapeutics
Ionizing Radiation
S Phase
Transcriptome
Cisplatin
Genes
Radiotherapy
Cell Culture Techniques
Genome
Gene Expression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bosco, E. E., Wang, Y., Xu, H., Zilfou, J. T., Knudsen, K. E., Aronow, B. J., ... Knudsen, E. S. (2007). The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. Journal of Clinical Investigation, 117(1), 218-228. https://doi.org/10.1172/JCI28803

The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. / Bosco, Emily E.; Wang, Ying; Xu, Huan; Zilfou, Jack T.; Knudsen, Karen E.; Aronow, Bruce J.; Lowe, Scott W.; Knudsen, Erik S.

In: Journal of Clinical Investigation, Vol. 117, No. 1, 04.01.2007, p. 218-228.

Research output: Contribution to journalArticle

Bosco, EE, Wang, Y, Xu, H, Zilfou, JT, Knudsen, KE, Aronow, BJ, Lowe, SW & Knudsen, ES 2007, 'The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer', Journal of Clinical Investigation, vol. 117, no. 1, pp. 218-228. https://doi.org/10.1172/JCI28803
Bosco, Emily E. ; Wang, Ying ; Xu, Huan ; Zilfou, Jack T. ; Knudsen, Karen E. ; Aronow, Bruce J. ; Lowe, Scott W. ; Knudsen, Erik S. / The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. In: Journal of Clinical Investigation. 2007 ; Vol. 117, No. 1. pp. 218-228.
@article{9991f18d28bc42f2a806bc07c6b30ce8,
title = "The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer",
abstract = "The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of human cancers and is aberrant in one-third of all breast cancers. RB regulates G1/S-phase cell-cycle progression and is a critical mediator of antiproliferative signaling. Here the specific impact of RB deficiency on E2F-regulated gene expression, tumorigenic proliferation, and the response to 2 distinct lines of therapy was investigated in breast cancer cells. RB knockdown resulted in RB/E2F target gene deregulation and accelerated tumorigenic proliferation, thereby demonstrating that even in the context of a complex tumor cell genome, RB status exerts significant control over proliferation. Furthermore, the RB deficiency compromised the short-term cell-cycle inhibition following cisplatin, ionizing radiation, and antiestrogen therapy. In the context of DNA-damaging agents, this bypass resulted in increased sensitivity to these agents in cell culture and xenograft models. In contrast, the bypass of antiestrogen signaling resulted in continued proliferation and xenograft tumor growth in the presence of tamoxifen. These effects of aberrations in RB function were recapitulated by ectopic E2F expression, indicating that control of downstream target genes was an important determinant of the observed responses. Specific analyses of an RB gene expression signature in 60 human patients indicated that deregulation of this pathway was associated with early recurrence following tamoxifen monotherapy. Thus, because the RB pathway is a critical determinant of tumorigenic proliferation and differential therapeutic response, it may represent a critical basis for directing therapy in the treatment of breast cancer.",
author = "Bosco, {Emily E.} and Ying Wang and Huan Xu and Zilfou, {Jack T.} and Knudsen, {Karen E.} and Aronow, {Bruce J.} and Lowe, {Scott W.} and Knudsen, {Erik S.}",
year = "2007",
month = "1",
day = "4",
doi = "10.1172/JCI28803",
language = "English (US)",
volume = "117",
pages = "218--228",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer

AU - Bosco, Emily E.

AU - Wang, Ying

AU - Xu, Huan

AU - Zilfou, Jack T.

AU - Knudsen, Karen E.

AU - Aronow, Bruce J.

AU - Lowe, Scott W.

AU - Knudsen, Erik S.

PY - 2007/1/4

Y1 - 2007/1/4

N2 - The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of human cancers and is aberrant in one-third of all breast cancers. RB regulates G1/S-phase cell-cycle progression and is a critical mediator of antiproliferative signaling. Here the specific impact of RB deficiency on E2F-regulated gene expression, tumorigenic proliferation, and the response to 2 distinct lines of therapy was investigated in breast cancer cells. RB knockdown resulted in RB/E2F target gene deregulation and accelerated tumorigenic proliferation, thereby demonstrating that even in the context of a complex tumor cell genome, RB status exerts significant control over proliferation. Furthermore, the RB deficiency compromised the short-term cell-cycle inhibition following cisplatin, ionizing radiation, and antiestrogen therapy. In the context of DNA-damaging agents, this bypass resulted in increased sensitivity to these agents in cell culture and xenograft models. In contrast, the bypass of antiestrogen signaling resulted in continued proliferation and xenograft tumor growth in the presence of tamoxifen. These effects of aberrations in RB function were recapitulated by ectopic E2F expression, indicating that control of downstream target genes was an important determinant of the observed responses. Specific analyses of an RB gene expression signature in 60 human patients indicated that deregulation of this pathway was associated with early recurrence following tamoxifen monotherapy. Thus, because the RB pathway is a critical determinant of tumorigenic proliferation and differential therapeutic response, it may represent a critical basis for directing therapy in the treatment of breast cancer.

AB - The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of human cancers and is aberrant in one-third of all breast cancers. RB regulates G1/S-phase cell-cycle progression and is a critical mediator of antiproliferative signaling. Here the specific impact of RB deficiency on E2F-regulated gene expression, tumorigenic proliferation, and the response to 2 distinct lines of therapy was investigated in breast cancer cells. RB knockdown resulted in RB/E2F target gene deregulation and accelerated tumorigenic proliferation, thereby demonstrating that even in the context of a complex tumor cell genome, RB status exerts significant control over proliferation. Furthermore, the RB deficiency compromised the short-term cell-cycle inhibition following cisplatin, ionizing radiation, and antiestrogen therapy. In the context of DNA-damaging agents, this bypass resulted in increased sensitivity to these agents in cell culture and xenograft models. In contrast, the bypass of antiestrogen signaling resulted in continued proliferation and xenograft tumor growth in the presence of tamoxifen. These effects of aberrations in RB function were recapitulated by ectopic E2F expression, indicating that control of downstream target genes was an important determinant of the observed responses. Specific analyses of an RB gene expression signature in 60 human patients indicated that deregulation of this pathway was associated with early recurrence following tamoxifen monotherapy. Thus, because the RB pathway is a critical determinant of tumorigenic proliferation and differential therapeutic response, it may represent a critical basis for directing therapy in the treatment of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=33845972969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845972969&partnerID=8YFLogxK

U2 - 10.1172/JCI28803

DO - 10.1172/JCI28803

M3 - Article

VL - 117

SP - 218

EP - 228

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -